References
- Kimura S, Ohkawara H, Ogawa K, et al. Lenalidomide as a beneficial treatment option for renal impairment caused by light chain deposition disease: a case series. Intern Med. 2018;57(24):3651–3657.
- Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica. 2009;94(2):300–302.
- Li XM, Rui HC, Liang DD, et al. Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single chinese center. Ann Hematol. 2016;95(6):901–909.
- Cohen C, Royer B, Javaugue V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015;88(5):1135–1143.
- Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–587.
- Toshiharu U, Kikuchi K, Hazue R, et al. Five sequential evaluations of renal histology in a patient with light chain deposition disease. Intern Med. 2016;55(20):2993–2999.
- Minarik J, Scudla V, Tichy T, et al. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma. 2012;53(2):330–331.
- Ioannis P, Stylianou K, Mavroeidi V, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant. 2010;25(6):2020–2023.